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The characteristics of HIV/AIDS patients with
deep vein thrombosis at Dr George Mukhari
Academic Hospital
I. Govender
Medunsa, Pretoria, South Africa
Background: Deep vein thrombosis (DVT) is ten times more
prevalent in HIV/AIDS patients than the general population.
HIV/AIDS has also been shown to be a hypercoagulable state which
is worsened by conditions like malignancies, opportunistic infec-
tions, some auto-immune diseases and chemotherapeutic agents.
Methods & Materials: This was a cross sectional, descriptive
study looking at all HIV/AIDS patients admitted to level one wards
at the hospital without DVT.
Results: Variable Frequency Percent
On HAART 6 35%
On Tuberculosis treatment 8 47%
Improvement of DVT 16 94%
Pneumonia excluding Tuberculosis 4 24%
Discharged on warfarin 17 100%
Attempted suicide 2 12%
Cerebro vascular accident 1 6%
Gastroenteritis 4 24%
Anaemia – recorded 2 12%
Mean duration of admission 14.1 days
Conclusion: Patients with HIV/AIDS and opportunistic infec-
tions, or other predisposing factors such as immobility are more
likely to develop DVTs.
http://dx.doi.org/10.1016/j.ijid.2016.02.581
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The proﬁles of HIV-infected patients treated at
A. Wahab Sjahranie General Hospital
Samarinda, Indonesia
C. Gunawan
A. Wahab Sjahranie General Hospital, Samarinda,
Indonesia
Background: The number of HIV-infected patients and deaths-
related to HIV are increasing rapidly in Indonesia. Studies about
the proﬁles of HIV-infected patients can be useful to create better
approaches for prevention and treatment.
The aimof this studywas to evaluate the proﬁles ofHIV-infected
patientswho got ARV treatment in VCT clinic at A.Wahab Sjahranie
General Hospital Samarinda.
Methods & Materials: This study was conducted at A.
Wahab Sjahranie General Hospital in Samarinda, East Kalimantan,
Indonesia from December 2005 to September 2015. Subjects were
HIV-infected patients who got ARV treatment at VCT clinic.
Results: Until September 2015 there were 394 patients who
had taken ARV, 96 (24.4%) of them had died. Among 298 patients
who were on ARV treatment, there were 172 males (57.7%) and
126 females (42.3%) with ages distribution were as follow : ≤ 10
years 10 (3.4%), 11-20 years 11 (3.7%), 21-30 years 118 (39.6%), 31-
40 years 104 (34.9%), 41-50 years 36 (12.0%), > 50 years 19 (6.4%).
Routes of transmission were as follow : sexual 274 (91.9%), IDU 10
(3.4%), mother to child 10 (3.4%), others 4 (1.3%). CD4 levels when
starting ARV : < 50 : 107 (35.9%), 51-100 : 59 (19.8%), 101-200 : 69
(23.2%), 201-350 : 43 (14.4%), 351-500 : 14 (4.7%), > 500 : 6 (2.0%).
The most common ARV regimen used for adults was TDF-3TC-EFV
(71.8%). Patients who started taking ARV when pregnant were 19
(6.4%). Adherence to ARV : > 95% 227 (76.2%), 80-95% 23 (7.7%), <
80% 48 (16.1%).
Conclusion: The majority of patients who get ARV treatment at
VCT clinic of A. Wahab Sjahranie General Hospital Samarinda are
youngpeople (21-40yearsold), and themajor routeof transmission
is sexual intercourse. Most of the patients start taking ARV in a late
phase of infection which is correlated with poor prognosis.
http://dx.doi.org/10.1016/j.ijid.2016.02.582
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Metabolic syndrome among people living with
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G.R. Jammy1,∗, M. Dinaker2, P.S. Reddy3, C.H.
Bunker1
1 Graduate School of Public Health, University of
Pittsburgh, Pittsburgh, USA
2 GYD Reference Laboratory, Hyderabad, India
3 SHARE INDIA, MediCiti Institute of Medical
Sciences, Ghanpur, Hyderabad, India
Background: India ranks third in the world for number of peo-
ple living with HIV (PLHIV). Anti-Retroviral Therapy (ART) has
led to decline of morbidity and mortality, making HIV a chronic
manageable disease. This increased life span extends exposure
to environmental/lifestyle risk factors contributing cardiovascular
diseases (CVD) and other diseases of aging. Metabolic syndrome
(MS) is a clustering of risk factors for CVD, and an important pub-
lic health concern. Globally prevalence of MS among PLHIV varies
from 11 – 45%, but data are sparse on MS among PLHIV in India.
We describe the prevalence of MS among PLHIV population from
southern India.
Methods & Materials: A cross-sectional study with non-
probability consecutive sampling in a private clinic of Hyderabad
was carried out. Adult PLHIV under the care of the physician
consultant, with informed consent, were included in the study
irrespective of their ART status. Structured questionnaire, anthro-
pometric measurement and fasting blood samples were drawn.
Metabolic syndromewas deﬁned using International Diabetes Fed-
eration (IDF) and U.S. National Cholesterol Education Program
Adult Treatment Panel III (ATPIII) criteria, with speciﬁc cut offs
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for Asian Indians. Highly sensitive C Reactive Protein (Hs-CRP), a
marker of inﬂammation and of CVD risk, was also measured. The
study aims at recruiting 400 PLHIV; we present the preliminary
ﬁndings of 225 participants.
Results: Therewere63%males.Meanagewas43years, 7.5 years
mean duration sinceHIV diagnosis, and 97% initiated onART. Based
on the ATPIII, 52% (57% Males & 42% Females) and IDF 46% (49%
Males & 41 Females)met the criteria forMS. Agewas higher among
PLHIV with MS by either criteria. 40% had >3 mg/dl Hs-CRP levels,
with males (median 2.37, Q1 1.1, Q3 4.25) and females (median
2.31, Q1 1.2, Q3 4.97) similar statistically. The Hs-CRP levels were
not associated with MS categorized by ATP III or IDF criteria.
Conclusion: The overall prevalence ofMS and theHs-CRP levels
were high in this PLHIV population. With the diverse and incon-
sistent evidence globally on the CVD risk associated with MS and
Hs-CRP amongPLHIV, further research efforts are required to delin-
eate this dual burden among PLHIV.
http://dx.doi.org/10.1016/j.ijid.2016.02.583
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Retrospective analyses of CD4 count monitoring
to detect ART response
M. Katiyar1,∗, R. Singh1, S.C. Parija2
1 Jawharlal Institute of Postgraduate Medical
Education & Research, Puducherry, Puducherry,
India
2 Jawaharlal Institute of Postgraduate Medical
Education and Research, Puducherry, Puducherry,
India
Background: National AIDS Control Programme was launched
in 1992 by National AIDS Control Organization for prevention and
control of HIV/AIDS in India. Viral load testing is a preferred test to
monitor treatment response of antiretroviral therapy (ART). How-
ever, for more than two decades, CD4 cell count measurements
have been used as a major marker in understanding HIV disease
progression, making important clinical decisions, and monitoring
the response to ART. In India, most of the laboratories have been
using CD4 count for monitoring the response of ART. The study is
undertaken because there is limited data available about response
to ART.
Methods&Materials:HIV caseswhopresentedat theARTclinic
of JIPMER and were on ART from September 2014 to August 2015
were included in the retrospective study. Patient demographic
details and CD 4 count were recorded. A patient on ART was con-
sidered non-responsive to the ART if the CD 4 count didn’t rise after
six month of ART regime.
Results: A total of 581 HIV positive patients presented at the
ART clinic of JIPMERduring the studyperiod. 300 (51.6%)weremale
and 281 (48.4%) were female. 448 patients (77%) were resident of
Tamil Nadu and 133 (23%) were from Pondicherry. 442 patients
(76%) were on ART and CD4 count were recorded. CD 4 count of
126 (28.5%) patients didn’t rise from their previous CD4 count and
were considerednon-responsive to theART. 69 (54.8%)were female
and 57 (45.2%) were male.
Conclusion: In resource limited settings CD4 count testing is
most commonly done to monitor the ART response in HIV positive
patients. Itwoulddetect treatment failure andsupport clinical deci-
sion for starting the patient on second line ART. 28.5% of patients on
ART didn’t observe improvement in their CD 4 count. These cases
were observed more in females (54.8%) than males (45.2%). It may
be due to due to non-compliance of ART by these patients. There is
a risk of development of HIV drug resistance in these cases. Large
scale of similar study will be required to generate broader data
which will facilitate better ART care.
http://dx.doi.org/10.1016/j.ijid.2016.02.584
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Association of nadir CD4 counts with
carotid-intima media thickness and
inﬂammation markers in HIV infected patients
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Background: During HIV infection, apart from use of PI-based
regimen, low CD4+ T-cell count has also been identiﬁed as a vas-
cular risk factor. Initiating ART in patients with higher nadir CD4
counts is speculated to better normalise CVD risks and inﬂamma-
tory response. We aimed to study effect of nadir CD4 count on CVD
and inﬂammatory response in ART naive and treated HIV patients.
Methods & Materials: Cross-sectional enrolment of 169
HIV-infected patients (68 naive; 101 ART experienced) with dif-
ferent nadir CD4 counts; Drug Naive(DN)- Group 1 (n=24;Nadir
CD4<350cells/L); Group2 (n=44;Nadir CD4>350cells/L); ART
experienced- Group 3 (n=32;Nadir CD4 <200cells/L);Group 4
(n=36;Nadir CD4 200-350cells/L);Group 5 (n=33;Nadir CD4
>350cells/L) and Group 6 (n=29 healthy controls (HC) were done.
Wemeasured serum lipid proﬁle (LP), C-IMT, cardiac output, TNFR-
1, TNFR-2 for inﬂammation, sCD14 for microbial translocation
(MT) by ELISA. Descriptive statistics were used for demographics;
ANOVA to identify differences in LP, C-IMT, cardiac output, inﬂam-
mation, MT between groups.
Results: Mean age, median current and nadir CD4 count
for groups 1-5: 37.7±5.6, 123.5(70-273.5), 123.5(70-273.5);
35.36±5.2, 534(440-595), 572(496.5-761.25); 38.7±5.7, 138.5(83-
167.5), 569(430.25-773.5); 38.3±5.9, 273.5(228.5-317.5), 717(564-
867.5); 40.3±5.1, 402(378-438), 777(649-1005); 37±5.9. C-IMT
